DNAG.OB

[evgeny05]

Hello !

Interesting charts !

http://stockcharts.com/def/servlet/SC.web?c=DNAG

Regards.
Evgeny.

[gmarc66]

Yes, looks like it wants to start its way back up again...good volume.

Are u in? i'm considering...price is still on the low side.

thanks,

julia

[evgeny05]

Hello !

DNAPrint genomics' Business Partner Biofrontera AG Completes 20 Million Euro Bond Placement
Tuesday September 6, 7:00 am ET


SARASOTA, Fla., Sept. 6, 2005 (PRIMEZONE) -- DNAPrint(tm) genomics, Inc. (OTC BB:DNAG.OB - News), which holds an 18% stake in German pharmaceutical company Biofrontera AG, today announced that Biofrontera has completed a 20 million euro bond placement.
ADVERTISEMENT




The bonds began trading on the Frankfurt exchange on Wednesday, August 31, under the symbol (ISIN DE 000 A0E 964 9). If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock. This conversion rate attributes a price of 16.13 euros per share to the Biofrontera common shares. If this accurately represents the fair market value of the Biofrontera common stock, then DNAPrint's 455,179 shares of Biofrontera stock, which it acquired for 1.5 million euros in July 2005, would now be valued at approximately 7.3 million euros.

``We believe our investment in Biofrontera will prove to be beneficial to DNAPrint genomics and to our shareholders,'' said DNAPrint genomics President and Chief Executive Officer Richard Gabriel. ``It validates our decision to build a collaborative relationship with Biofrontera in advance of its anticipated initial public offering.''

``Biofrontera is an excellent business partner for us because of its drug-product pipeline,'' said Hector J. Gomez, Ph.D., Chairman and Chief Medical Officer at DNAPrint genomics. ``We are pleased with our relationship with Biofrontera, and we have the highest confidence in its management team. We are confident the new funding will assist Biofrontera in advancing its drugs into the market.''

Mr. Gabriel and Dr. Gomez both are members of Biofrontera's Board of Directors.

``DNAPrint genomics, Inc. and its support were crucial to our securing this new financing,'' said Prof. Hermann Lubbert, Chief Executive Officer of Biofrontera AG. ``We look forward to building our relationship with DNAPrint and believe that the synergy of the two companies and their technologies may offer a faster, cheaper and more effective way to develop drugs,'' he concluded.

Biofrontera already is in Phase II clinical trials for its lead product, an anti-itch compound for chronic Urticaria, or chronic itching. It also has a Phase II clinical trial compound for pre-cancerous skin lesions. In addition, Biofrontera has advanced several compounds to pre-clinical development, including a novel prophylactic migraine treatment.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. (http://www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a ``Super EPO'' (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWitness(tm) RETINOME(tm) (a predictive test for inferring eye color from a DNA sample), ANCESTRYbyDNA(tm), and EURO-DNA(tm). Recently announced and as a part of the Company's Trace Genetics acquisition, DNAWitness-Y and DNAWitness-Mito are two new tests that can be used as identification tools when other DNA testing either fails to yield results or the sample might be too deteriorated.

About Biofrontera AG

Biofrontera is aiming to become a specialty pharma business in dermatology and inflammatory diseases. The company is located in Leverkusen, Germany. Biofrontera's existing investor group includes Heidelberg Innovation, TechnoMedia Kapitalbeteiligungsgesellschaft Koln mbH, and Prof. Dr. Riesner, founder of Quiagen AG. The financial resources provided by the bond will be applied to the further development of Biofrontera's clinical products. The bond will be placed on the Frankfurt Exchange under the symbol (ISIN DE 000 A0E 964 9).

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



Contact:
          DNAPrint genomics, Inc.
          Richard Gabriel, CEO and President
          941-366-3400

          The Wall Street Group, Inc.
          Ron Stabiner
          212-888-4848

[IAmTheMan]

In my only post on here this is one of my big picks for future. Hold it for several years. This and BLYC.ob

Though the DNAG might have more potential once they get the drugs on market. Look at what 
Genentech Inc. (DNA)
did.

$41-$94 in less then 1 year. Once DNAG gets the ball rolling. It will skyrocket up so fast you won't be able to get in anymore.

Buy it when people bash the stock. That is only chance to get it for pennies.

[higherstocks]

Hey Iamtheman,  Looks oversold.  What do you know about the company?  Looks interesting to me.  Any info would be appreciated.

Thx

[IAmTheMan]

This page here shows you the product pipeline and how far they are into them.

http://www.dnaprint.com/welcome/pipeline/

This is the grandaddy page.

http://www.dnaprint.com/welcome/investorrelations/


Check them out guy. Worth the investment.

[evgeny05]

Hi !

http://www.market-pulse.com/eyiiprofile.htm

DNAG - UP 15%
VOL - 1.409.032



Good luck.
Evgeny.

[IAmTheMan]

Anyone catch them on COURT TV last night at 9pm? Cool stuff. I would back the truck up and load up. Better yet, back 3 trucks up!

This is better then 1 share of Google any day this stock.

[poorman1]

Opened a position at $.0257.    I agree that the stock is oversold.  The company is loosing money, but something big must be brewing.

A 20 Million Euro Bond Placement for Biofrontera is significant and DNA Print has an 18% stake in Biofrontera, which may have a public offering.

"If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock".

This is a lot of seed money.  They must have a high expectation of Biofrontera having a public offering.

IMO  This would cause DNAG stock to greatly appreciate from it's puny $1.8MM market cap.

poorman1

[higherstocks]

Looking at the RSI this should bounce any day now, why oversold so I am in tommorrow morning.    Going to play the bounce.  My predition on this will be .10-.12 cents bouncing through through.

[digitx]

Looking at the RSI this should bounce any day now, why oversold so I am in tommorrow morning.    Going to play the bounce.  My predition on this will be .10-.12 cents bouncing through through.

I bought this stock at an average of 0.22 before DNAG split 20-1. Then the price slipped down to as low as 0.065. Now it is climbing up. Do you think that this stock will go as high as 0.12 or would it at least go back to its original 0.22.

TIA

[higherstocks]

This thing is so oversold I think this is skyrocketing to .18 next week.

[digitx]

This thing is so oversold I think this is skyrocketing to .18 next week.

Higherstocks,

Do you think this will go higher than its initial 0.22 in the coming weeks? As I said I bought it before the split of 20 to 1 and that was low at that time. I just want to know if it will regain at least its original value.

Thanks for all your help.

-digitx

[higherstocks]

Im not sure but I do know that this is way oversold.  If I were you I would buy more at this level and really bank.  Nothing is 100% but when I see RSI so low it is almost a given that when it does rebound it will explode.

[digitx]

Thanks for the great advice. Monday morning I will get more at this low price then if and when it goes to say 0.18 it will balance out and make a profit.

Thank you again. I really appreciate your help and prompt response.

-digitx